Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness
- PMID: 38750156
- DOI: 10.1007/s00270-024-03730-z
Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness
Abstract
Purpose: To develop a model based on whole-liver radiomics features of pre-treatment enhanced MRI for predicting the prognosis of hepatocellular carcinoma (HCC) patients undergoing continued transarterial chemoembolization (TACE) after TACE-resistance.
Materials and methods: Data from 111 TACE-resistant HCC patients between January 2014 and March 2018 were retrospectively collected. At a ratio of 7:3, patients were randomly assigned to developing and validation cohorts. The whole-liver were manually segmented, and the radiomics signature was extracted. The tumor and liver radiomics score (TLrad-score) was calculated. Models were trained by machine learning algorithms and their predictive efficacies were compared.
Results: Tumor stage, tumor burden, body mass index, alpha-fetoprotein, and vascular invasion were revealed as independent risk factors for survival. The model trained by Random Forest algorithms based on tumor burden, whole-liver radiomics signature, and clinical features had the highest predictive efficacy, with c-index values of 0.85 and 0.80 and areas under the ROC curve of 0.96 and 0.83 in the developing cohort and validation cohort, respectively. In the high-rad-score group (TLrad-score > - 0.34), the median overall survival (mOS) was significantly shorter than in the low-rad-score group (17 m vs. 37 m, p < 0.001). A shorter mOS was observed in patients with high tumor burden compared to those with low tumor burden (14 m vs. 29 m, p = 0.007).
Conclusion: The combined radiomics model from whole-liver signatures may effectively predict survival for HCC patients continuing TACE after TACE refractoriness. The TLrad-score and tumor burden are potential prognostic markers for TACE therapy following TACE-resistance.
Keywords: Artificial intelligence; Hepatocellular carcinoma; Prognosis; Radiomics; TACE refractoriness.
© 2024. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
References
-
- Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93. https://doi.org/10.1016/j.jhep.2021.11.018 . - DOI - PubMed
-
- Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology. 2020;72(1):198–212. https://doi.org/10.1002/hep.31022 . - DOI - PubMed
-
- Golfieri R, Bargellini I, Spreafico C, et al. Patients with Barcelona clinic liver cancer stages B and C hepatocellular carcinoma: time for a subclassification. Liver Cancer. 2019;8(2):78–91. https://doi.org/10.1159/000489791 . - DOI - PubMed
-
- Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and possibilities of transarterial chemotherapeutic treatment of hepatocellular carcinoma. Int J Mol Sci. 2021;22(23):13051. https://doi.org/10.3390/ijms222313051 . - DOI - PubMed - PMC
-
- Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181–223. https://doi.org/10.1159/000514174 . - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous